Thyroid Hormone Receptor Beta Agonists for VLCFA Reduction in X-ALD

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for improved methods to treat X-linked adrenoleukodystrophy (X-ALD), a disorder caused by mutations in the ABCD1 gene leading to the accumulation of very long chain fatty acids, as current treatments are limited and there is no cure.

Innovation Solution

Administering a thyroid hormone receptor beta agonist, such as a phosphonic acid containing compound or its salt, ester, or prodrug, to subjects with X-ALD, at specific dosages and schedules to manage the accumulation of very long chain fatty acids.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for X-ALD, then current therapy limitations are maintained, but no effective reduction of VLCFA accumulation is achieved

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtherapy options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the pharmacological parameter by introducing thyroid hormone receptor beta agonists (specific compounds with phosphonic acid groups) to activate alternative peroxisomal beta-oxidation pathways. This parameter change in receptor activation enables VLCFA degradation in patients with ABCD1 mutations, directly resolving the treatment effectiveness contradiction.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If ABCD1 function is deficient due to mutations, then VLCFA transport into peroxisomes is impaired, but VLCFA accumulation in tissues continues to increase

Engineering Contradiction:

ImproveVLCFA degradationVSAvoidmetabolic pathway dependency

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces thyroid hormone receptor beta agonists as intermediary substances that mediate between the defective ABCD1 transporter and VLCFA degradation. These compounds activate alternative pathways (including ABCD2-mediated transport and peroxisomal beta-oxidation enzymes) to bypass the defective ABCD1 function, resolving the contradiction between transporter deficiency and degradation need.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If no approved therapy exists for X-ALD, then treatment options are limited, but patient outcomes remain poor with rapid progression to vegetative state

Engineering Contradiction:

Improveapproved therapiesVSAvoiddisease progression control

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent employs preliminary action by administering thyroid hormone receptor beta agonists to activate peroxisomal beta-oxidation pathways before severe neurological damage occurs. The compounds (such as those with phosphonic acid groups) are designed to preemptively reduce VLCFA accumulation and delay or prevent progression to vegetative state, addressing the lack of approved therapies.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The administration of thyroid hormone receptor beta agonists effectively reduces the accumulation of very long chain fatty acids, improving the condition of X-ALD patients by enhancing ABCD2 expression and VLCFA beta-oxidation.

Implementation Method 1

enhancing ABCD2 expression and VLCFA beta-oxidation

Methodology Applied

Scientific EffectBeta-oxidation:

Data Source

PatentUS12440502B2Use of thyroid beta-agonists

Publication Date: 2025.10.14 VIKING THERAPEUTICS INC

AI summary

Methods useful for treating X-linked adrenoleukodystrophy are provided.